Tag Archives: ARWR

Monday’s Midday Stock Update: Karyopharm Therapeutics (KPTI), Peabody Energy Comm (BTU), Arrowhead Research (ARWR), Blueprint Medicines (BPMC), Aerie Pharma (AERI)

So far Monday, December 2, NASDAQ is down -4.72% and the S&P is down -2.6%. Here are this morning’s most active stocks: Karyopharm Therapeutics (KPTI – Research Report), Peabody Energy Comm (BTU – Research Report), Arrowhead Research (ARWR – Research

Friday’s Midday Movers: Clovis Oncology (CLVS), TG Therapeutics (TGTX), Blueprint Medicines (BPMC), Arrowhead Research (ARWR), United States Steel (X)

So far Friday, November 29, NASDAQ is up 0.26% and the S&P is down -0.36%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Clovis Oncology (CLVS – Research Report), TG Therapeutics (TGTX –

Arrowhead Research (ARWR) Receives a Buy from Chardan Capital

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Arrowhead Research (ARWR – Research Report) today and set a price target of $81.00. The company’s shares closed last Monday at $69.02, close to its 52-week high of $70.28. According

Tuesday’s Midday Movers: Arrowhead Research (ARWR), Clovis Oncology (CLVS), Ambarella (AMBA), Best Buy Co (BBY), Amarin (AMRN)

So far Tuesday, November 26, NASDAQ is down -0.46% and the S&P is up 0.6%. Here are this morning’s most active stocks: Arrowhead Research (ARWR – Research Report), Clovis Oncology (CLVS – Research Report), Ambarella (AMBA – Research Report), Best

Monday’s Midday Movers: Clovis Oncology (CLVS), Arrowhead Research (ARWR), Splunk (SPLK), Exact Sciences (EXAS), Zogenix (ZGNX)

So far Monday, November 25, NASDAQ is up 2.64% and the S&P is up 0.83%. Here are this morning’s most active stocks: Clovis Oncology (CLVS – Research Report), Arrowhead Research (ARWR – Research Report), Splunk (SPLK – Research Report), Exact

Cantor Fitzgerald Keeps a Hold Rating on Arrowhead Research (ARWR)

Cantor Fitzgerald analyst Elemer Piros maintained a Hold rating on Arrowhead Research (ARWR – Research Report) today and set a price target of $50.00. The company’s shares closed last Monday at $48.17, close to its 52-week high of $49.78. According